TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Qualigen Therapeutics ( (QLGN) ) just unveiled an announcement.
On July 28, 2025, Qualigen Therapeutics announced a private placement of its Series A-3 Preferred Stock, raising $4.5 million in gross proceeds. The company plans to use the funds for working capital and potentially for investor relations. The Series A-3 Preferred Stock is convertible into common stock and includes anti-dilution protections. The issuance has also triggered an adjustment to the conversion price of the company’s Series A-2 Preferred Stock, reflecting the company’s strategic financial maneuvers to strengthen its market position.
Spark’s Take on QLGN Stock
According to Spark, TipRanks’ AI Analyst, QLGN is a Underperform.
Qualigen Therapeutics’ overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.
To see Spark’s full report on QLGN stock, click here.
More about Qualigen Therapeutics
Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases. The company’s pipeline includes QN-302, a selective G-quadruplex inhibitor targeting various tumor types including pancreatic cancer; QN-247, a nucleolin-targeting compound for hematologic malignancies; and a family of small-molecule RAS oncogene protein-protein interaction inhibitors, all designed to address areas of high unmet medical need, with potential for orphan drug designation.
Average Trading Volume: 838,548
Technical Sentiment Signal: Sell
Current Market Cap: $4.58M
Find detailed analytics on QLGN stock on TipRanks’ Stock Analysis page.